Precigen’s PAPZIMEOS Launch Drives Surging Q1 Revenue

Precigen, Inc. ((PGEN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Precigen’s latest earnings call struck an upbeat tone as management spotlighted a rapid commercial ramp for PAPZIMEOS alongside broad payer adoption and early signs of durable clinical benefit. Investors were also reminded of elevated near‑term cash burn and heavier SG&A tied to launch, but management’s confidence in reaching cash‑flow breakeven by 2026 underpinned an overall constructive outlook.

Explosive PAPZIMEOS Launch Fuels Revenue Surge

PAPZIMEOS delivered its first full‑quarter punch with Q1 2026 net product revenue of $21.6 million, up from just $3.4 million in Q4 2025, a roughly 535% quarter‑over‑quarter jump. That performance drove total quarterly revenue to $23.3 million, signaling a powerful start for Precigen’s inaugural commercial therapy and setting a high bar for subsequent quarters.

Broad Payer Coverage Opens Door to Most U.S. Patients

Management emphasized that an estimated 297 million covered lives now have access to PAPZIMEOS across commercial plans, Medicare and Medicaid. This footprint represents more than 90% of insured U.S. lives and positions the therapy for wide uptake as awareness grows among both specialists and frontline community physicians.

Patient Hub Metrics Highlight Early Community Reach

Approximately 400 patients were registered in Precigen’s patient hub at the time of the call, offering an early gauge of demand funneling through the company’s support infrastructure. Notably, about a quarter of these patients originated from community settings, underscoring penetration beyond major academic centers and hinting at broad real‑world adoption.

Permanently Assigned J‑Code Streamlines Reimbursement

A permanent J‑code for PAPZIMEOS took effect on April 1, 2026, a key administrative win that should simplify billing and claims processing. Management expects this coding milestone to quicken reimbursement cycles and reduce friction for providers, which could accelerate both prescribing behavior and revenue recognition over time.

Durable Clinical Data and Upcoming ASCO Update

Precigen underscored that patients have shown durable responses with a median follow‑up of roughly three years, a crucial data point for clinicians weighing long‑term benefit. Updated durability data are slated for presentation at ASCO next month, and management expects these results to reinforce confidence in PAPZIMEOS and support continued label strength.

First‑in‑Class Launch Backed by Expert Endorsement

The call highlighted that PAPZIMEOS represents the first commercial therapeutic launch in recurrent respiratory papillomatosis history, marking a milestone for the field. A landmark expert position paper from a group of 16 U.S. physicians, under the RRP Foundation, recommends PAPZIMEOS as preferred first‑line therapy, providing influential validation that should bolster physician adoption.

Operating and Net Losses Tempered by Launch Revenue

Precigen reported a Q1 operating loss of $6.0 million, which management described as modest given the early stage of commercialization. Net loss came in at $7.9 million, or $0.02 per share, reflecting how rapid revenue growth from PAPZIMEOS is already offsetting a substantial portion of operating costs during the launch phase.

Funding Runway to Projected 2026 Cash‑Flow Breakeven

The company ended the quarter with $56.7 million in cash, cash equivalents and investments, forming the backbone of its self‑funding strategy. Management reiterated that this balance, combined with collections from PAPZIMEOS receivables, should carry Precigen to cash‑flow breakeven by the end of 2026, and they currently see no need to tap capital markets.

Pipeline Advances and New Indications in Sight

Beyond the launch, Precigen is preparing a pediatric trial for PAPZIMEOS, targeted to begin in the fourth quarter of 2026, extending the therapy into younger populations. The company also highlighted progress for PRGN‑2009 from its AdenoVerse platform in multiple Phase II trials with pembrolizumab for HPV‑16/18‑driven cancers, with further updates expected later this year.

High First‑Quarter Cash Burn Flags Execution Risk

Cash used in operations reached $43.8 million in Q1, a sizeable outflow that raised investor attention around execution discipline and working‑capital dynamics. Management noted that about $13 million of this usage reflected non‑recurring items, but the quarter still showcased elevated cash consumption that they aim to bring down in coming periods.

SG&A Swells on Launch‑Driven Commercial Spending

Selling, general and administrative expenses climbed to $21.0 million, an $8.7 million increase versus the prior‑year quarter, as Precigen built out commercial infrastructure. While the roughly 70% year‑over‑year rise underscores the cost of scaling a launch, leadership framed these investments as critical to sustaining PAPZIMEOS momentum and driving long‑term profitability.

R&D Pullback Now, Reacceleration Expected Later

R&D expenses fell to $5.6 million in Q1, down $4.8 million from the year‑ago period, largely due to prior manufacturing costs being expensed before approval. Management cautioned that R&D is likely to trend higher as the year progresses, with spending tied to the planned pediatric trial, redosing studies and continued development of the broader pipeline.

Receivables and Payment Terms Delay Cash Inflows

Despite strong PAPZIMEOS sales, Precigen recorded no cash receipts from those sales in Q1, reflecting standard customer payment terms that push collections into later quarters. The company stressed that converting these receivables into cash is central to its runway forecast and near‑term liquidity profile, making working‑capital management a key metric to watch.

Limited Transparency on Dosing and Conversion Metrics

Management chose not to disclose precise patient dosing counts, hub‑to‑treatment conversion rates or detailed time‑to‑dose metrics, citing the early stage of launch analytics. They suggested it may take another quarter or two before releasing meaningful conversion data, leaving investors to rely on top‑line revenue and hub registrations as proxy indicators.

Absence of Numeric Revenue Guidance Near Term

The company declined to provide formal numeric guidance for Q2 or the full year, limiting modeling precision despite commentary on continued acceleration. Management did, however, signal confidence that PAPZIMEOS momentum will carry into Q2 and beyond, with more concrete visibility expected when they report Q2 results in August.

Management Outlook Centers on Momentum and Discipline

Precigen reiterated that PAPZIMEOS launch strength should persist into Q2, pointing to the steep revenue ramp from $3.4 million in Q4 2025 to $21.6 million in Q1 2026. They forecast significantly lower cash used in operations in Q2, expect existing cash and receivable collections to bridge the company to cash‑flow breakeven by end‑2026, and plan additional clinical updates on durability, redosing and PRGN‑2009 later this year.

The earnings call painted a picture of a company riding strong early traction for a first‑in‑class therapy while actively managing the growing pains of commercialization. For investors, the mix of robust revenue growth, broad payer access and expert endorsement, balanced against high initial cash burn and limited short‑term guidance, frames Precigen as a high‑potential story where execution over the next few quarters will be critical.